摘要
目的:检测分化抑制因子id1在人骨肉瘤组织中的表达情况,并分析与患者临床特点、肺转移及两年生存率的关系。方法:运用免疫组织化学法检测39例人骨肉瘤,20例骨软骨瘤组织中id1的表达情况,结合临床资料和随访结果进行统计分析。结果:骨肉瘤组织中id1的表达明显高于骨软骨瘤,差异具有统计学意义(P<0,05),其表达水平与患者Enneking临床分级有关,与患者年龄、性别无关。id1表达阳性的患者肺转移发生率高于阴性患者,两年生存率低于阴性患者。结论:id1在人骨肉瘤组织中高度表达,并与患者肺转移,两年生存率密切相关,可能作为骨肉瘤生物治疗的新靶点。
Objective：To detect the expression of idl in human osteosarcoma tissues and to analyze its association with clinical characteristics,lung metastasis and two-year survival rate of patients.Methods： The expression of id1 was examined by immunohistochemical method in 39 cases of human osteosarcoma tissues and 20 cases of osteochondroma.Statistical analysis was based on clinical and follow-up data.Results： The expression of id1 in osteosarcoma was significantly higher than that in osteochondroma.The difference had statistical significance（P0.05）.Its expression level had close correlation with Enneking clinical staging,but no relationship with age and gender.Patients with positive expression of id1 had higher rate of lung metastasis and lower two-year survival rate.Conclusion： idl was highly expressed in human osteosarcoma tissues which was close correlated with lung metastasis and two year survival rate.Id 1 may be used in biological therapy of osteosarcoma as a new target.
出处
《激光杂志》
CAS
CSCD
北大核心
2012年第2期67-68,共2页
Laser Journal
基金
国家自然科学基金(30901530)
关键词
骨肉瘤
肺转移
两年生存率
ID1
osteosarcoma
lung metastasis
two-year survival rate
id1
